高级检索
当前位置: 首页 > 详情页

MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Oncology, Clinical and Basic Research Team of Traditional Chinese Medicine Prevention and Treatment ofNon-Small Cell Lung Cancer, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China, [2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, [3]Guangdong Provincial Key Laboratory of ClinicalResearch on Traditional Chinese Medicine Syndrome, Guangzhou, China, [4]Guangdong Pharmaceutical University,Guangzhou, China
出处:
ISSN:

关键词: miR-24 cancer initiation progression biomarker

摘要:
MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers. On the one hand, miR-24 was reported to be down-regulated in some types of cancer, indicating its role as a tumor suppressor. On the other hand, it has shown that miR-24 was up-regulated in some other types of cancer, even in the same type of cancer, suggesting the role of miR-24 being as an oncogene. Firstly, miR-24 was dysregualted in human cancers, which is related to the clinical performance of cancer patients. Thus miR-24 could be used as a potential non-invasive diagnostic marker in human cancers. Secondly, miR-24 was associated with the tumor initiation and progression, being as a promoter or inhibitor. Therefore, miR-24 might be an effective prognostic biomarker in different type of cancers. Lastly, the abnormal expression of miR-24 was involved in the chemo- and radio- therapies of cancer patients, indicating the role of miR-24 being as a predictive biomarker to cancer treatment. Totally, miR-24 contributes to tumorigenesis, tumor progression, and tumor therapy, which closely related to clinic. The present review shows that miR-24 plays a double role in human cancers and provides plenty of evidences to apply miR-24 as a potential novel therapeutic target in treating human cancers.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Oncology, Clinical and Basic Research Team of Traditional Chinese Medicine Prevention and Treatment ofNon-Small Cell Lung Cancer, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China, [2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, [3]Guangdong Provincial Key Laboratory of ClinicalResearch on Traditional Chinese Medicine Syndrome, Guangzhou, China,
共同第一作者:
通讯作者:
通讯机构: [1]Department of Oncology, Clinical and Basic Research Team of Traditional Chinese Medicine Prevention and Treatment ofNon-Small Cell Lung Cancer, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China, [2]Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, [3]Guangdong Provincial Key Laboratory of ClinicalResearch on Traditional Chinese Medicine Syndrome, Guangzhou, China,
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号